Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-3712 in Healthy Adult Volunteers and Patients With Atopic Dermatitis

NCT07205081 is registered in ClinicalTrials.gov with Attovia Therapeutics Inc as lead sponsor.

NCT NCT07205081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07205081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-3712 in Healthy Adult Volunteers and Patients With Atopic Dermatitis
Lead sponsor
Attovia Therapeutics Inc
Phase
Phase 1
Overall status
Completed
Start date
October 22, 2025
Completion date
August 13, 2026
Enrollment
48 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad), atopic eczema, atopic eczema/dermatitis (non-specific), normal volunteers